It is the pot of gold at the end of the medical rainbow—the promise that, by harnessing data, researchers can tailor drugs, devices, and treatments to the genetic configuration, lifestyle, and environment of individual patients.
A rapidly aging population, along with economic growth and rising industrialization, is driving a big increase of the disease.
This mode of personalized medicine helps doctors make more informed decisions related to drug therapies.
Digital reality technologies are fast emerging as promising tools to aid physicians and patients. Western and Asian medtech companies are becoming big players in the growing market for these new applications in Asia.
Although many device companies are seeking cost savings when seeking sourcing products or components manufactured in Asia, quality should not be compromised. Intense due diligence is important.
Breast cancer is on the rise across Asia, with more women contracting the disease than ever before.
Although pharmaceuticals are the main treatment route, medical devices are needed to fight the disease on a new level.
The need is growing for life-saving treatments.
Although the market is expected to experience strong growth, the quality of care is inconsistent.
With the exception of a few countries, Asia’s disease management industry is relatively unstructured.